Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.37 |
| ▸ | JAK1 | P23458 | 5/20 | 0.37 |
| ▸ | JAK3 | P52333 | 3/20 | 0.36 |
| ▸ | FASN | P49327 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24120430 | 0.91 | JAK3 (0.34) | JAK2JAK3FASNIRAK4TBK1 | |
| SCHEMBL21361296 | 0.90 | MAPK1 (0.44) | IRAK4PIK3CAMTORENPP2ATXN2 | |
| SCHEMBL21361283 | 0.89 | CYP1A2 (0.41) | FASNIRAK4PIK3CAMTOR | |
| SCHEMBL21361291 | 0.88 | FASN (0.37) | FASNIRAK4ENPP2ATXN2 | |
| SCHEMBL24324810 | 0.88 | ACACA (0.35) | FASNPIK3CAMTORCNR2P2RX7 | |
| SCHEMBL21361287 | 0.87 | IRAK4 (0.37) | FASNIRAK4PIK3CAMTORCNR2 | |
| SCHEMBL21361286 | 0.86 | IRAK4 (0.36) | FASNIRAK4PIK3CAMTORTBK1 | |
| SCHEMBL24324819 | 0.85 | FASN (0.35) | FASNCNR2P2RX7 | |
| SCHEMBL21361301 | 0.85 | GRM5 (0.45) | FASN | |
| SCHEMBL24120318 | 0.85 | PDCD1LG2 (0.36) | JAK2JAK1JAK3FASNIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765445-B1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-08-30 | — | — | EP | disclosed |
| US-20210000113-A1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-01-07 | — | — | US | disclosed |
| WO-2019175117-A1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000113-A1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | CBR3, DDT, CBR1 | JAK2 3641/4885JAK1 4550/4885JAK3 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.